| Title： | Atrial fibrillation: Current knowledge and recommendations for treatment -- 2021 |
| Edition： | Updated |
| Classification： | Standard guideline |
| Field： | Diagnosis and Treatment |
| Countries and regions： | China |
| Guidelines users： | |
| Evidence classification method： | "Class A evidence: evidence from more than one high-quality randomized controlled Ttrial (RCT); Meta-analysis of high-quality RCTS; One or more RCTS confirmed by a high quality registry study. Grade B evidence was divided into: Grade B-R (Randomized), from one or more medium-quality RCT evidence; Meta-analysis of moderate-quality RCTS; Class B-NR (Non-randomized) derived from one or more well-designed and executed non-randomized, observational, or registered studies or meta-analyses of the above studies. Level C evidence is classified as: Limited data (C-LD), limited design or execution of randomized or non-randomized observational or registry studies or meta-analysis of the above studies, physiological or mechanistic studies of human subjects; C-eo (Expert Opinion), based on the consensus of clinical expertise. " |
| Development unit： | Chinese Society of Pacing and Electrophysiology、Chinese Society of Arrhythmias、Chinese Alliance of Atrial Fibrillation Centers |
| Registration time: | 2021-12-08 |
| Registration number： | IPGRP-2021CN406 |
| Purpose of the guideline: |
CURRENT Guidelines INFORMATION
Uploader：Tangyanhongrenminyiyuan
Upload Date：2021-12-08
Latest registration
